Noxopharm Limited (ASX:NOX)

Australia · Delayed Price · Currency is AUD

0.0920

-0.0030 (-3.16%)

Aug 26, 2026, 4:10 PM AEST

-12.38% (1Y)

Market Cap	29.19M -4.9%
Revenue (ttm)	3.40M +44.8%
Net Income	-5.49M
EPS	-0.02
Shares Out	307.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,491
Open	0.0920
Previous Close	0.0950
Day's Range	0.0890 - 0.0920
52-Week Range	0.0510 - 0.1150
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Noxopharm

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company als... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 7

Stock Exchange Australian Securities Exchange

Ticker Symbol NOX

Full Company Profile

Financial Performance

In fiscal year 2025, Noxopharm's revenue was 2.82 million, an increase of 17.52% compared to the previous year's 2.40 million. Losses were -4.88 million, 36.5% more than in 2024.

Financial Statements